# Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

> **NCT03657160** · PHASE3 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 343 (actual)

## Conditions studied

- Hematopoietic Stem Cells

## Interventions

- **DRUG:** Vedolizumab Placebo
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT03657160
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-06
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-05-09
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03657160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03657160, "Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03657160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*